Literature DB >> 10646634

Inhibition of rabbit keratocyte and human fetal lens epithelial cell proliferation by retrovirus-mediated transfer of antisense cyclin G1 and antisense MAT1 constructs.

J Kampmeier1, A Behrens, Y Wang, A Yee, W F Anderson, F L Hall, E M Gordon, P J McDonnell.   

Abstract

The aim of this study is to evaluate the potential of gene transfer of cell cycle control genes as treatment of corneal haze or secondary cataract formation. The guiding hypothesis is that strategic modulation of the cyclin G1 or MAT1 gene by retrovirus-mediated gene transfer will inhibit proliferation of rabbit keratocytes (RabK) and fetal human lens epithelial (FHLEpi) cells in vitro. RabK and FHLEpi cell cultures were transduced in triplicate with retroviral vectors bearing either a nuclear-targeted beta-galactosidase, an antisense cyclin G1 (aG1), an antisense MAT1 (aMAT1) construct, or the neo(r) gene. The presence of beta-galactosidase activity in the transduced cultures was detected by immunohistochemical X-Gal staining, while cyclin G1 and MAT1 protein expression levels were evaluated by Western analysis. Proliferation of RabKs and FHLEpi cells was analyzed by counting the number of cells in the aG1 and aMAT1 vector-transduced cultures over 5 days. The mean transduction efficiency was 34.4% (SD 1.41) for RabKs and 19.7% (SD 1.83) for FHLEpi cells. Downregulation of cyclin G1 and MAT1 protein expression was noted 24 hr after transduction of RabK cultures with the respective vectors. Cytostatic effects of the aG1 and aMAT1 vectors in both RabKs and FHLEpi cells were most pronounced on the fifth day (RabKs, p < 0.0007; FHEpi cells, p < 0.001). An increased incidence of apoptosis was identified in both aG1 and MAT1-transduced FHLEpi cells. Taken together, these data suggest the potential utility of developing aG1 and aMAT1 retroviral vectors in gene therapy protocols for corneal haze and secondary cataract formation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10646634     DOI: 10.1089/10430340050016102

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  7 in total

1.  Lysine-independent turnover of cyclin G1 can be stabilized by B'alpha subunits of protein phosphatase 2A.

Authors:  Hongyun Li; Koji Okamoto; Melissa J Peart; Carol Prives
Journal:  Mol Cell Biol       Date:  2008-11-03       Impact factor: 4.272

2.  ELAS1-mediated inhibition of the cyclin G1-B'γ interaction promotes cancer cell apoptosis via stabilization and activation of p53.

Authors:  S Ohno; Y Naito; S Mukai; N Yabuta; H Nojima
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

3.  Identification and functional clustering of global gene expression differences between human age-related cataract and clear lenses.

Authors:  John R Hawse; James F Hejtmancik; Quingling Huang; Nancy L Sheets; Douglas A Hosack; Richard A Lempicki; Joseph Horwitz; Marc Kantorow
Journal:  Mol Vis       Date:  2003-10-07       Impact factor: 2.367

4.  Inhibition of proliferation of rabbit lens epithelial cells by S-phase kinase-interacting protein 2 targeting small interfering RNA.

Authors:  Ying Su; Feng Wang; Qinghui Yan; Yan Teng; Hao Cui
Journal:  Mol Vis       Date:  2010-05-25       Impact factor: 2.367

5.  Comprehensive phenotypic analysis of knockout mice deficient in cyclin G1 and cyclin G2.

Authors:  Shouichi Ohno; Jun-Ichiro Ikeda; Yoko Naito; Daisuke Okuzaki; Towa Sasakura; Kohshiro Fukushima; Yukihiro Nishikawa; Kaori Ota; Yorika Kato; Mian Wang; Kosuke Torigata; Takashi Kasama; Toshihiro Uchihashi; Daisaku Miura; Norikazu Yabuta; Eiichi Morii; Hiroshi Nojima
Journal:  Sci Rep       Date:  2016-12-16       Impact factor: 4.379

Review 6.  MicroRNA involvement in hepatocellular carcinoma.

Authors:  Laura Gramantieri; Francesca Fornari; Elisa Callegari; Silvia Sabbioni; Giovanni Lanza; Carlo M Croce; Luigi Bolondi; Massimo Negrini
Journal:  J Cell Mol Med       Date:  2008-12       Impact factor: 5.310

7.  Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy - A review of molecular mechanisms for oncologists.

Authors:  Erlinda M Gordon; Joshua R Ravicz; Seiya Liu; Sant P Chawla; Frederick L Hall
Journal:  Mol Clin Oncol       Date:  2018-06-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.